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Impact of in vivo T-cell depletion on outcome of AML patients in
ﬁrst CR given peripheral blood stem cells and reduced-intensity
conditioning allo-SCT from a HLA-identical sibling donor: a
report from the Acute Leukemia Working Party of the European
group for Blood and Marrow Transplantation
F Baron1, M Labopin2,3,4,5, D Blaise6, L Lopez-Corral7, S Vigouroux8, C Craddock9, M Attal10, P Jindra11, H Goker12, G Socie´13,
P Chevallier14, P Browne15, A Sandstedt16, RF Duarte17, A Nagler18 and M Mohty2,3,4,5
The impact of in vivo T-cell depletion on transplantation outcomes in patients transplanted with reduced-intensity conditioning
(RIC) remains controversial. This study assessed the outcome of 1250 adult patients with de novo AML in ﬁrst CR (CR1) given PBSC
from HLA-identical siblings after chemotherapy-based RIC. A total of 554 patients did not receive any form of in vivo T-cell depletion
(control group), whereas antithymocyte globulin (ATG) and alemtuzumab were given in 444 and 252 patients, respectively. The
incidences of grade II-IV acute GVHD were 21.4, 17.6 and 10.2% in control, ATG and alemtuzumab patients, respectively (Po0.001).
In multivariate analysis, the use of ATG and the use of alemtuzumab were each associated with a lower risk of chronic GVHD
(Po0.001 each), but a similar risk of relapse, and of nonrelapse mortality, and similar leukemia-free survival and OS. Further, among
patients given BU-based RIC, the use of o6mg/kg ATG did not increase the risk of relapse (hazard ratio, HR¼ 1.1), whereas there
was a suggestion for higher relapse risk in patients givenX6mg/kg ATG (HR¼ 1.4, P¼ 0.08). In summary, these data suggest that a
certain amount of in vivo T-cell depletion can be safely used in the conditioning of AML patients in CR1 given PBSC after
chemotherapy-based RIC.
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INTRODUCTION
The use of PBSC instead of BM in patients receiving grafts from
HLA-matched donors after myeloablative conditioning has been
associated with faster hematological recovery, lower relapse risk in
patients with advanced disease (due to higher immune-mediated
graft-versus-tumor (GVT) effects), but also higher incidence
extensive chronic GVHD.1–4 These observations prompted
several groups of investigators to study in vivo T-cell depletion
of the graft with antithymocyte globulin (ATG) or alemtuzumab as
a way to reduce severe GVHD in patients given PBSC after high-
dose myeloablative conditioning regimen.5–7 These studies
demonstrated that the use of ATG or alemtuzumab was
successful at preventing severe GVHD without apparently
increasing the relapse incidence (RI).5–7 In contrast to patients
given grafts after myeloablative conditioning who beneﬁt from
both the high-dose chemo/radiotherapy given as part of the
conditioning regimen and the GVT effect for tumor eradication,
patients given grafts after reduced-intensity conditioning regimen
(RIC) rely mainly on the GVT effect for tumor eradication.8–13
Thus, given the tight association between occurrence of
GVHD and the GVT effect,14–18 one might hypothesized that
in vivo T-cell depletion in the RIC setting might be detrimental
because of high risk of tumor relapse. In agreement with
this hypothesis, a recent study from the Center for International
Blood and Marrow Transplant Research (CIBMTR) observed
that that in vivo T-cell depletion with ATG or alemtuzumab
increased the RI and decreased disease-free survival in a cohort
of 1676 patients with various hematological malignancies
given BM or PBSC from HLA-matched or HLA-mismatched
related or unrelated donors after chemotherapy-based RIC.19
This study aimed to investigate these ﬁndings in a more
homogeneous cohort of 1250 adult patients with de novo AML
in ﬁrst CR (CR1) given PBSC from HLA-identical siblings after
chemotherapy-based RIC.
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This was a retrospective study performed by the Acute Leukemia Working
Party (ALWP) of the European group for Blood and Marrow Transplantation
(EBMT) group. EBMT registry is a voluntary working group of more than
500 transplant centers, participants of which are required once a year to
report all consecutive SCT and follow-up. The scientiﬁc board of the Acute
Leukemia Working Party of EBMT approved this study. Data of adult de
novo AML patients in CR1 at transplantation and given G-CSF-mobilized
PBSC from HLA-identical siblings between 2000 and 2011 after
chemotherapy-based RIC were included. Patients given ex vivo T-cell
depleted grafts were excluded. Grading of acute and chronic GVHD was
performed using established criteria.20 For the purpose of this study, all
necessary data were prospectively collected according to the EBMT
guidelines and using the EBMT Minimum Essential Data forms. List of
institutions reporting data included in this study is provided in the
supplemental data.
Statistical analysis
Data from all patients meeting the inclusion/exclusion criteria were
included in the analyses. Start time was date of transplant for all end
points. To evaluate probability of relapse (RI), patients dying either from
direct toxicity of the procedure or from any other cause not related to
leukemia were censored. The nonrelapse mortality (NRM) was deﬁned
as death while in CR. Patients were censored at the time of relapse or of
the last follow-up. Cumulative incidence curves were used for RI and NRM
in a competing risk setting, as death and relapse were competing
together.21
For estimating of the cumulative incidence of chronic GVHD, death was
considered as a competing event. OS and leukemia-free (LFS) survival rates
(starting from date of transplant) were calculated using the Kaplan–Meier
estimates. Univariate analyses were done using the Gray’s test for
cumulative incidence functions and the log rank test for OS and LFS.
Associations of patient and graft characteristics with grade II-IV acute
GVHD were evaluated using multivariate logistic regression. Associations of
patient and graft characteristics with other outcomes (chronic
GVHD, relapse, NRM, LFS and OS) were evaluated in multivariable analyses,
using Cox proportional hazards. Factors included in the Cox models
included the use of ATG in the conditioning (and dose of ATG in the
models for patients given BU-based RIC), the use of alemtuzumab in the
conditioning (and dose of alemtuzumab in the models for patients given
melphalan-based RIC), patient age, year of transplantation4 median, time
from diagnosis to transplantation 4 median, female donor to male
recipient versus other gender combinations, donor and recipient CMV
serostatus, poor risk cytogenetic or presence of an internal-tandem
duplication of Fms-like tyrosine kinase 3 (FLT3-ITD) and center activity. All
tests were two sided. The type I error rate was ﬁxed at 0.05 for
determination of factors associated with time to event outcomes.
The Bonferroni correction was applied for comparisons when ATG and
alemtuzumab patients were simultaneously compared with controls.
Statistical analyses were performed with SPSS 19 (SPSS Inc, Chicago, IL,




Data from 1250 patients given PBSC from HLA-identical siblings
were included in the current analysis (Table 1). Brieﬂy, 554 patients
(44%) did not receive any in vivo T-cell depletion (control patients),
whereas ATG and alemtuzumab were given in 444 (36%) and 252
(20%) patients, respectively. Centers that used ATG were mainly
located in France (231 patients (52%)), whereas centers that used
alemtuzumab were mainly located in UK (212 patients (84%)). The
proportion of patients with poor risk cytogenetics or Fms-like
tyrosine kinase 3-internal-tandem duplication was higher in ATG
patients (23%) than in control (17%) or alemtuzumab (18%)
patients (P¼ 0.04). RIC consisted of BU-containing regimens in
51% of control patients, 88% of ATG patients and 16% of
alemtuzumab patients, whereas 24% of control patients, 6% of
ATG patients and 83% of alemtuzumab patients received a
melphalan-based RIC (Po0.0001). We did not have complete data
on the use of pre-emptive DLI in the registry but at least 15 (5%)
control patients, 39 (14%) ATG patients and 66 (36%) alemtuzu-
mab patients received pre-emptive DLI (deﬁned as DLI given
before/without AML relapse). Finally, there were a higher
proportion of patients transplanted in low-activity centers22
(arbitrarily deﬁned as centers that contributed for p10 patients
in the current study) among control patients (55%) than among
ATG (43%) or alemtuzumab (44%) patients (Po0.001).
Impact of type of chemotherapy-based RIC on allo-SCT outcomes
among control patients
Given that the distribution of RIC regimens used varied among
control, ATG and alemtuzumab patients, we ﬁrst analyzed the
impact of the type of conditioning regimen (melphalan-based
versus BU-based versus other) on transplantation outcomes
among control patients (not given in vivo T-cell depletion).
Three-year incidences (±s.e.) of RI and NRM were 27±4% and
22±4%, respectively, in patients given melphalan-based RIC,
30±2% and 17±3%, respectively, in those given BU-based RIC
and 35±4% and 13±3%, respectively, in those given other
chemotherapy-based RIC (global P-values for RI and NRM: P¼ 0.13
and P¼ 0.18, respectively) (Figure 1). Three-year LFS and OS were
49±5% and 52±5%, respectively, in patients given melphalan-
based RIC 53±3% and 55±3%, respectively, in those given BU-
based RIC and 51±5%, and 60±5%, respectively, in those given
other chemotherapy-based RIC (global P-values for LFS and OS:
P¼ 0.99 and P¼ 0.37, respectively) (Figure 1).
Impact of in vivo T-cell depletion in the general population
Engraftment and GVHD. Five control patients (0.9%), four ATG
patients (0.9%) but no alemtuzumab patients failed to engraft
(P¼ 0.32). Secondary graft rejection occurred in 1 (0.18%), 1
(0.23%) and 1 (0.4%) control, ATG and alemtuzumab patients,
respectively. The 100-day incidences of grade II-IV acute GVHD in
control, ATG and alemtuzumab patients were 21.4%, 17.6%
(P¼ 0.13 in comparison with control patients) and 10.2%
(Po0.0001 in comparison with control patients and P¼ 0.01 in
comparison with ATG patients), respectively. The 100-day
incidences of grade III-IV acute GVHD in control, ATG and
alemtuzumab patients were 9.6%, 8.8% (P¼ 0.67 in comparison
with control patients) and 1.6% (Po0.0001 in comparison with
control patients and Po0.0001 in comparison with ATG patients),
respectively. In multivariate analysis, the only factor signiﬁcantly
associated with a low risk of grade II-IV acute GVHD was the use of
alemtuzumab (hazard ratio, HR¼ 0.4; 95% CI: 0.3–0.7, Po0.001).
With a median follow-up of 28 months (range, 1–138 months),
3-year cumulative incidences of chronic and extensive chronic
GVHD were 57±2% and 38±3%, respectively, in control patients,
39±3% (Po0.001 in comparison with control patients) and
19±2% (Po0.001 in comparison with control patients), respec-
tively, in ATG patients and 37±3% (Po0.001 in comparison with
control patients and P¼ 0.31 in comparison with ATG patients)
and 10±2% (Po0.001 in comparison with control patients and
P¼ 0.006 in comparison with ATG patients), respectively, in
alemtuzumab patients (Figure 2). In multivariate analysis, the use
of ATG and the use of alemtuzumab were each associated with a
lower risk of chronic GVHD (HR¼ 0.6 (95% CI, 0.5–0.8), Po0.001
and HR¼ 0.5 (95% CI, 0.4–0.6), Po0.001, respectively] and a lower
risk of extensive chronic GVHD (HR¼ 0.5 (95% CI, 0.3–0.6),
Po0.001 and HR¼ 0.2 (95% CI, 0.1–0.4), Po0.001, respectively).
No other factors were associated with the risk of chronic GVHD,
while longer time from diagnosis to transplantation was
associated with a lower risk of extensive chronic GVHD.
RI, NRM, OS and LFS. Three-year cumulative incidences of RI and
NRM were 31±2% and 17±2%, respectively, in control patients,
35±2% (P¼ 0.26 in comparison with control group) and 13±2%
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(P¼ 0.37 in comparison with control group), respectively, in ATG
patients and 33±3% (P¼ 0.88 in comparison with control group)
and 15±2% (P¼ 0.28 in comparison with control group),
respectively, in alemtuzumab patients. Three-year LFS and OS
were 51±2% and 55±2%, respectively, in control patients,
51±3% (P¼ 0.74 in comparison with control group) and
59±3% (P¼ 0.74 in comparison with control group), respectively,
in ATG patients and 52±3% (P¼ 0.29 in comparison with control
group) and 58±3% (P¼ 0.24 in comparison with control group),
respectively, in alemtuzumab patients. Causes of death included
relapse, GVHD, infection, graft rejection/failure or others in 111
(51.9%), 41 (19.2%), 31 (14.5%), 1 (0.5%) and 30 (14%) control
patients, respectively, 90 (53.3%), 27 (16%), 25 (14.8%), 1 (0.6%)
and 26 (15.4%) ATG patients, respectively, and 50 (56.2%), 11
(12.4%), 15 (16.9%), 1 (1.1%) and 12 (13.5%) alemtuzumab
recipients, respectively.
In multivariate analysis, the use of ATG and the use of
alemtuzumab were each associated with a similar risk of RI
(HR¼ 1.1, P¼ 0.40 and HR¼ 1.0, P¼ 0.75, respectively), a similar
risk of NRM (HR¼ 0.9, P¼ 0.60 and HR¼ 0.9, P¼ 0.57, respec-
tively) and similar LFS (HR¼ 1.0, P¼ 0.78 and HR¼ 0.9, P¼ 0.45,
respectively) and OS (HR¼ 0.9, P¼ 0.60 and HR¼ 0.9, P¼ 0.31,
respectively). Other factors associated with allo-SCT
outcomes included poor risk cytogenetics or Fms-like tyrosine
kinase 3-internal-tandem duplication positivity associated
with a higher risk of RI (HR¼ 1.8, Po0.001) leading to worse
LFS (HR¼ 1.4, P¼ 0.001) and OS (HR¼ 1.5, Po0.001), high
activity center associated with a lower RI (HR¼ 0.8, P¼ 0.02)
and lower NRM (HR¼ 0.7, P¼ 0.05) leading to improved
LFS (HR¼ 0.8, P¼ 0.004) and OS (HR¼ 0.8, P¼ 0.006), older
patient age at transplantation associated with higher NRM
(HR¼ 1.33 per 10 years, P¼ 0.002) leading to worse OS
(HR¼ 1.1, P¼ 0.04), and female donors to male recipients
associated with a higher risk of NRM (HR¼ 1.5, P¼ 0.02) leading
to worse LFS (HR¼ 1.2, P¼ 0.04) and OS (HR¼ 1.3, P¼ 0.02)
(Supplementary Table 1).
Table 1. Patients and transplant characteristics
Control (n¼ 554) ATG (n¼ 444) Alemtuzumab (n¼ 252) Global P-value a
Median patient age, y (range) 56 (19–76) 56 (19–74) 54 (23–70) 0.21
Median year of SCT, y (range) 2007 (00–11) 2008 (00–11) 2008 (00–11) 0.01
Recipient gender, % M 56 53 47 0.05
Donor gender, % M 54 56 56 0.81
Female donor/male recipient, % pts 23.4 21.9 19.5 0.48
Median WBC at diagn  109/L (range) 12.9 (0.1–700) 9.3 (0.2–879) 13 (0.1–274) 0.08
Median time form diagn to SCT, d (range) 154 (54–874) 166 (63–762) 158 (70–425) 0.05
Patient CMV seropositivity, n (%) 194 (72) 122 (66) 64 (60) 0.05
Donor CMV seropositivity, n (%) 186 (69) 112 (61) 60 (55) 0.02
Cytogenetics n (%)
Good riskb 14 (2.5) 15 (3.4) 5 (2.0)
Intermediate riskc 219 (39.5) 193 (43.5) 110 (43.7)
High risk or FLT3-ITD positived 95 (17.1) 103 (23.2) 44 (17.5) 0.04
Not reported 226 (40.8) 133 (30.0) 93 (36.9)
Conditioning (RIC), n (%)e o0.0001
Melphalan-based RIC 134 (24) 25 (6) 209 (83)
Fludarabine-melphalan 133 (24) 25 (6) 207 (82)
Other melphalan-based 1 (0.2) 0 2 (1)
BU-based RIC 285 (51) 389 (88) 40 (16)
Fludarabine–BU 272 (49) 379 (85) 39 (15)
Other BU based 13 (2) 10 (2) 1 (0.5)
Other chemotherapy-based RIC 135 (24) 30 (7) 3 (1)
In vivo T-cell depletion, n (%)
None 554 (100) 0 0
ATG o6mg/kg 0 202 0
ATG X6mg/kg 0 144 0
ATG dose unknown 0 98 0
Alemtuzumab o80mg 0 0 124
Alemtuzumab X80mg 0 0 33
Alemtuzumab dose unknown 0 0 95
Postgrafting immunosuppression, n (%) o0.0001
Tacro or CSPþMtx 383 (70) 90 (21) 30 (12)
Tacro or CSPþMMF 110 (20) 123 (29) 20 (8)
Tacro or CSP alone 54 (10) 217 (50) 199 (80)
Unknown 7 14 3
Center activity, n (%) o0.0001
Higher (410 patients in current survey) 250 (45.1) 252 (56.8) 141 (56.0)
Lower (p10 patients in current survey) 304 (54.9) 192 (43.2) 111 (44.0)
Abbreviations: ATG¼ antithymocyte globulin; diagn¼diagnosis; F¼ female; FLT3-ITD¼ Fms-like tyrosine kinase 3-internal-tandem duplication; M¼male;
MMF¼mycophenolate mofetil; Pts¼patients; RIC¼ reduced-intensity conditioning; tacro¼ tacrolimus; Y¼ year. aCalculated with the w2 or the Kruskal–Wallis
test. bDefined as t(8;21), t(15;17), inv or del (16), or acute promyelocytic leukemia, these abnormalities only or combined with others. cDefined as all
cytogenetics not belonging to the good or high risk (including trisomias). dDefined as 11q23 abnormalities, complex karyotype and abnormalities of
chromosomes 5 and 7. eDefined as use of fludarabine associated with BU p8mg/kg or other nonmyeloablative drugs.
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Given that most ATG recipients were given BU-based RIC
and that most alemtuzumab recipients were given a melphalan-
based RIC, we further assessed the impact of in vivo
T-cell depletion by comparing allo-SCT outcomes between
controls and ATG patients given a BU-based RIC and
between control and alemtuzumab patients given a melphalan-
based RIC.
Impact of ATG among patients given BU-based RIC
Among patients given BU-based RIC (n¼ 674, excluding patients
given alemtuzumab), acute GVHD of grade II, III and IV were
observed in 29 (10%), 16 (6%) and 12 (4%) control patients
(n¼ 271 with complete information), respectively, and in 36 (9%),
21 (5%) and 12 (3%) ATG patients (n¼ 379 with completed
information) (P¼ 0.35 for the incidence of grade II-IV acute GVHD).
Three-year cumulative incidences of chronic and extensive chronic
GVHD were 55±4% and 41±4% in control patients, respectively,
and 38±3% (P¼ 0.001) and 18±2% (Po0.0001) in ATG patients,
respectively. In univariate analysis, the use of ATG was associated
with similar incidences of relapse (32±4 versus 27±4 in control
group at 3-year; P¼ 0.25), lower NRM (13±2 versus 22±4 at
3-year in control group; P¼ 0.02), not signiﬁcant difference for LFS
(55±4 versus 49±5 at 3-year; P¼ 0.20) and OS (60±4 versus
52±5 at 3-year; P¼ 0.08) (Figure 3). In multivariate analyses, the
use of ATG was associated with a lower incidence of chronic GVHD
(HR¼ 0.6, P¼ 0.002 in patients given ATG at a doseo6mg/kg and
HR¼ 0.6, P¼ 0.03 in patients given ATG at a doseX6mg/kg).
Further, patients given o6mg/kg ATG had similar RI than those
not given ATG (HR¼ 1.1, P¼ 0.9), while there was a suggestion for
a higher RI in patients given ATG at a doseX6mg/kg (HR 1.4, 95%
CI, 1.0–2.1, P¼ 0.08) (Table 2). Finally, ATG administration was not
associated with NRM, LFS or OS.
Impact of alemtuzumab among patients given melphalan-based
RIC
Among patients given melphalan-based RIC (n¼ 343,
excluding patients given ATG), acute GVHD of grade II, III and IV
were observed in 19 (14%), 8 (6%) and 7 (5%) control
patients (n¼ 130 with completed data), respectively, and in 16
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Figure 1. Cumulative incidence of relapse (global P-value¼ 0.13) (a), cumulative incidence of nonrelapse mortality (global P-value¼ 0.18) (b),
leukemia-free survival (global P-value ¼ 0.99) (c) and OS (global P-value ¼ 0.37) (d) among patients conditioned with BU-based RIC (n¼ 285)




























Figure 2. Cumulative incidence of chronic GVHD in control (——),
ATG (– – –) and alemtuzumab patients (- - - -).
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with complete information), respectively (Po0.001 for the
incidence of grade II-IV acute GVHD). Three-year cumulative
incidences of chronic and extensive chronic GVHD were
51±5% and 32±5% in control patients, respectively, and
36±4% (P¼ 0.01) and 8±2% (Po0.0001) in
alemtuzumab patients, respectively. In univariate analysis, the
use of alemtuzumab was associated with a non-statistically
signiﬁcant suggestion of higher RI (32±4 versus 27±4 at
3-year; P¼ 0.25) but also a lower NRM (13±2 versus 22±4;
P¼ 0.02), translating toward a slight trend for better LFS
(55±4 versus 49±5; P¼ 0.20) and a trend for better OS (60±4
versus 52±5; P¼ 0.08) (Figure 4). In multivariate analyses, the use
of alemtuzumab was associated with a lower incidence of chronic
GVHD (HR¼ 0.4, Po0.001 in patients given alemtuzumab at a
doseo80mg/kg) but did not have a signiﬁcant impact on RI, NRM,
LFS or OS (Table 3).
Table 2. Multivariate analyses of transplant outcomes among patients given BU-based RIC and no alemtuzumab (n¼ 674)
cGVHD Progression/relapse Nonrelapse mortality LFS OS
HRa (95% CI) P-valuea HRa (95% CI) P-valuea HRa (95% CI) P-valuea HRa (95% CI) P-valuea HRa (95% CI) P-valuea
Use of ATG
No (n¼ 285) 1.0 1.0 1.0 1.0 1.0
1–6mg/kg (n¼ 196) 0.6 (0.4–0.8) 0.002 1 (0.7–1.4) 0.87 1.1 (0.6–1.8) 0.82 1.0 (0.7–1.3) 0.95 0.9 (0.7–1.3) 0.60
X6mg/kg (n¼ 111) 0.6 (0.4–1.0) 0.03 1.4 (1.0–2.1) 0.08 0.9 (0.5–1.7) 0.76 1.2 (0.9–1.7) 0.20 0.9 (0.6–1.3) 0.52
Dose unknown (n¼ 82) 0.7 (0.5–1.1) 0.16 0.8 (0.5–1.3) 0.36 0.7 (0.3–1.5) 0.40 0.8 (0.5–1.2) 0.21 0.8 (0.5–1.3) 0.38
Year of transplantation
4median
1.0 (0.7–1.3) 0.76 1.2 (0.9–1.6) 0.33 1.3 (0.8–2.0) 0.29 1.2 (0.9–1.6) 0.16 1.2 (0.9–1.6) 0.26
Patient age/10 years 1.0 (0.9–1.2) 0.58 1.0 (0.9–1.2) 0.86 1.3 (1.1–1.8) 0.02 1.1 (1.0–1.2) 0.15 1.1 (1.0–1.3) 0.13
Diagnosis to allo-SCT
4median
0.8 (0.6–1.1) 0.14 0.8 (0.6–1.1) 0.10 0.9 (0.6–1.3) 0.46 0.8 (0.6–1.0) 0.09 0.8 (0.6–1.1) 0.17
Female donor to male
recipient (n¼ 146)
1.1 (0.8–1.5) 0.63 0.9 (0.7–1.3) 0.69 1.4 (0.9–2.3) 0.12 1.1 (0.8–1.4) 0.61 1.1 (0.8–1.5) 0.42
Patient CMV
seropositivity (n¼ 463)
0.8 (0.6–1.1) 0.17 0.9 (0.6–1.2) 0.35 1.1 (0.7–1.9) 0.62 0.9 (0.7–1.2) 0.58 1.0 (0.7–1.4) 0.96
Donor CMV seropositivity
(n¼ 406)
1.5 (1.1–2.1) 0.007 0.9 (0.7–1.2) 0.53 1.7 (1.0–2.8) 0.05 1.1 (0.8–1.4) 0.58 1.1 (0.8–1.5) 0.55
Poor cytogenetics or
FLT3-ITD (n¼ 139)
1.0 (0.7–1.4) 0.88 1.8 (1.3–2.5) o0.001 1.1 (0.6–1.9) 0.75 1.6 (1.2–2.1) 0.001 1.7 (1.3–2.3) o0.001
High activity centersb
(n¼ 362)
1.1 (0.8–1.4) 0.68 0.8 (0.6–1.1) 0.17 0.8 (0.5–1.2) 0.21 0.8 (0.6–1.0) 0.06 0.8 (0.6–1.0) 0.05
Abbreviations: ATG¼ antithymocyte globulin; CI¼ confidence interval; FLT3-ITD¼ Fms-like tyrosine kinase 3-internal-tandem duplication; HR¼hazard ratio;
LFS¼ leukemia-free survival; RIC¼ reduced-intensity conditioning. aStatistically significant factors are in bold. bArbitrarily defined as center that contributed




























































































Figure 3. Cumulative incidence of relapse (a), cumulative incidence of nonrelapse mortality (b), leukemia-free survival (c) and OS (d) among
control patients conditioned with BU-based RIC (n¼ 285) (——) versus ATG (– – –) patients given BU-based RIC (n¼ 389).
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DISCUSSION
Although GVHD has been linked to the GVT effect after RIC allo-
SCT for AML,15,17,18,23 only a limited or moderate form of chronic
GVHD have been correlated with improved transplantation
outcomes.18 The current study indicates that 56% of AML
patients in CR1 given PBSC from HLA-identical siblings after
chemotherapy-based RIC in EBMT-afﬁliated centers have received
in vivo T-cell depleting agents (that is, ATG or alemtuzumab) with
the aim of preventing severe GVHD. However, a recent study from
the CIBMTR observed that, among patients given RIC allo-SCT
from related or unrelated donors for various hematological
malignancies, in vivo T-cell depletion decreased disease-free
survival due to a high incidence of disease relapse/
progression.19 This prompted us to perform the current study
that aimed to assess the impact of in vivo T-cell depletion on
transplantation outcomes in a more homogeneous population of
AML patients in CR1 given PBSC from HLA-identical siblings.
Several observations could be drawn from this analysis. First,
the use of in vivo T-cell depletion was successful at preventing
GVHD, in line with previously published data.5–7,19,24 Interestingly,
acute GVHD prevention seemed stronger in patients receiving




























































































Figure 4. Cumulative incidence of relapse (a), cumulative incidence of nonrelapse mortality (b), leukemia-free survival (c) and OS (d)
among control patients conditioned with melphalan-based RIC (n¼ 134) (——) versus alemtuzumab patients given melphalan-based RIC
(n¼ 209) (- - - -).
Table 3. Multivariate analyses of transplant outcomes among patients given melphalan-based RIC and no ATG (n¼ 343)
cGVHD Progression/relapse Nonrelapse mortality LFS OS
HRa (95% CI) P-valuea HRa (95% CI) P-valuea HRa (95% CI) P-valuea HRa (95% CI) P-valuea HRa (95% CI) P-valuea
Use of Alemtuzumab
No (n¼ 134) 1.0 1.0 1.0 1.0 1.0
o80mg (n¼ 108) 0.4 (0.2–0.6) o0.001 1.2 (0.7–2.1) 0.52 0.5 (0.2–1.1) 0.09 0.8 (0.5–1.3) 0.37 0.8 (0.5–1.2) 0.26
480mg (n¼ 26) 0.4 (0.2–1.2) 0.12 1.4 (0.6–3.3) 0.50 0.6 (0.2–2.1) 0.46 0.9 (0.5–1.9) 0.85 0.9 (0.4–1.9) 0.75
Dose unknown (n¼ 75) 0.6 (0.4–1.0) 0.04 1.2 (0.7–2.0) 0.60 0.6 (0.3–1.2) 0.13 0.8 (0.5–1.3) 0.38 0.7 (0.4–1.1) 0.13
Year of transplantation 4median 0.8 (0.5–1.3) 0.35 0.8 (0.4–1.4) 0.39 0.9 (0.4–1.8) 0.73 0.8 (0.5–1.3) 0.36 0.8 (0.5–1.2) 0.28
Patient age/10 years 1.1 (0.8–1.3) 0.55 0.9 (0.7–1.2) 0.66 1.1 (0.8–1.6) 0.45 1.0 (0.8–1.2) 0.83 1.1 (0.9–1.3) 0.59
Diagnosis to allo-SCT 4median 1.1 (0.8–1.7) 0.58 1.0 (0.6–1.5) 0.87 1.6 (0.9–2.9) 0.11 1.1 (0.8–1.6) 0.49 1.1 (0.8–1.6) 0.55
Female donor to male recipient
(n¼ 66)
1.6 (1.0–2.6) 0.06 1.3 (0.8–2.2) 0.34 1.2 (0.6–2.4) 0.71 1.2 (0.8–1.9) 0.39 1.3 (0.8–2.1) 0.23
Patient CMV seropositivity (n¼ 223) 1.2 (0.8–1.9) 0.44 1.1 (0.7–1.8) 0.61 1.9 (0.8–4.2) 0.13 1.3 (0.9–2.0) 0.16 1.3 (0.9–2.1) 0.17
Donor CMV seropositivity (n¼ 191) 0.7 (0.5–1.1) 0.17 1.0 (0.6–1.5) 0.88 1.5 (0.8–3.0) 0.20 1.2 (0.8–1.7) 0.44 1.2 (0.8–1.8) 0.41
Poor cytogenetics or FLT3-ITD
(n¼ 64)
0.8 (0.5–1.3) 0.37 1.6 (1.0–2.7) 0.04 0.5 (0.2–1.3) 0.16 1.2 (0.8–1.9) 0.36 1.3 (0.9–2.1) 0.19
High-activity centersb (n¼ 197) 0.9 (0.6–1.3) 0.56 1.0 (0.6–1.5) 0.86 0.6 (0.4–1.2) 0.15 0.8 (0.6–1.2) 0.33 0.7 (0.5–1.0) 0.07
Abbreviations: CI¼ confidence interval; FLT3-ITD¼ Fms-like tyrosine kinase 3-internal-tandem duplication; HR¼hazard ratio; LFS¼ leukemia-free survival;
RIC¼ reduced-intensity conditioning. aStatistically significant factors are in bold. bArbitrarily defined as center that contributed for410 patients in the current
study.
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the relatively low doses of ATG (o6mg/kg) given in the majority
of ATG recipients in the current survey as recent reports
demonstrated a direct link between ATG dosage and GVHD
incidence in patients given chemotherapy-based RIC.26–28
Second, ATG administration was not associated with a higher
risk of disease relapse/progression in patients with de novo AML in
ﬁrst CR when the dose of ATG was o6mg/kg (while there was a
suggestion for an increased RI when the dose of ATG wasX6mg/
kg). This observation is in line with previous studies performed in
patients given grafts after myeloablative conditioning showing
that low or moderate doses of ATG did not signiﬁcantly increase
the RI,5,7 but are in disagreement with the ‘RIC in vivo T-cell
depletion’ CIBMTR study mentioned above.19 Possible explanation
for this discrepancy could be that a high proportion of patients
(47%) in the CIBMTR study had lymphoid malignancies given that
previous studies have observed a tight association between in vivo
T-cell depletion of the graft and high RI in patients transplanted as
treatment for multiple myeloma or lymphoma.29,30 This
observation is also in agreement with data from the French
registry that showed poorer OS in patients given ﬂudarabine and
BU-based RIC in various hematological malignancies when the
dose of ATG (Thymoglobuline) was X10mg/kg total dose,31
whereas a recent single center study observed similar RI (P¼ 0.6)
in patients given BU-based RIC for myeloid malignancies when the
dose of ATG Thymoglobuline was increased from 2.5mg/kg total
dose to 5mg/kg total dose.28 Although we did not collect the
brand of ATG used in the registry, Thymoglobulin is by far the
most frequently used in Europe (and was most likely the ATG
brand for all patients given o6mg/kg ATG total dose), followed
by ATG Fresenius, whereas horse-derived formulations of ATG are
not available in Europe.
Interestingly, the use of alemtuzumab was not associated either
with higher relapse risk. This is different to what we have
previously observed in AML patients in CR1 given grafts from
unrelated donors after chemotherapy-based RIC, where alemtu-
zumab patients had higher RI and lower LFS and OS than ATG
patients,32 and to what has been observed in a survey including
patients given grafts from related or unrelated donors in CR1 or
CR2 at transplantation but that excluded patients given pre-
emptive DLI.18 Possible explanations for these apparent
discrepancies could be that the dose of alemtuzumab received
was lower in related than in unrelated recipients or that it was
possible to prevent relapse in alemtuzumab patients with
persistent mixed chimerism and in those with minimal residual
disease persistence by giving pre-emptive DLI,33 a strategy that
might have been less possible/successful in the unrelated donors
setting.34,35 Although we did not have complete data on pre-
emptive DLI in the registry precluding us to rigorously analyse the
impact of pre-emptive DLI in current patients, pre-emptive DLI
were given more frequently in alemtuzumab patients (36%) than
in control (5%) or ATG (14%) patients. Another strategy used to
prevent AML relapse after alemtuzumab-based RIC has been
based on the pre-emptive administration of azacitidine which can
likely favor the GVT effect without excessive GVHD.36,37
Besides the impact of in vivo T-cell depletion on outcomes, this
study also conﬁrmed the negative impact of poor risk cytoge-
netics,23,38,39 of being transplanted with a female donor in case of
male recipients,40 and of being transplanted in low-activity
centers18,22 on OS and PFS, as previously observed by our
group18,22,38,41 and by other groups of investigators.39,40 Further,
in contrast to what was observed in a recent CIBMTR study,39
current data suggest that older patient age at transplantation is
associated with higher NRM translating to worse LFS and OS in
multivariate analyses.
There are limitations in this study including its retrospective
design, and the fact that we did not have complete data on the
use of pre-emptive DLI. We tried to limit as much as possible
the impact of potential confounding factors by selecting a
population as homogeneous as possible (only PBSC recipients
(given the previously demonstrated lower incidence of cGVHD in
marrow recipients), only related recipients (given that the vast
majority unrelated PBSC recipients were given in vivo T-cell
depletion in the registry), only chemotherapy-based RIC (given
than very few TBI-based RIC recipients were given in vivo T-cell
depletion), and only CR1 patients), and by performing multivariate
analyses separately in patients given BU-based RIC and melpha-
lan-based RIC.
In summary, these data suggest that in vivo T-cell depletion
witho6mg/kg ATG can be safely used in the conditioning of AML
patients in CR1 given PBSC after BU-based RIC and that in vivo
T-cell depletion with alemtuzumab did not alter OS/PFS in AML
patients in CR1 given PBSC after melphalan-based RIC, at
least when pre-emptive DLI were given in selected patients.
Randomized prospective studies are needed to conﬁrm these
important data.
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